Henry Prince

CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.

Friyana K Bhabha, Christopher McCormack, Belinda A Campbell, Stephen Lade, Odette Buelens, Carrie Van Der Weyden, H Miles Prince

Journal article  |  2023  |  Australas J Dermatol

The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymph..

The Importance of Frailty Assessment in Multiple Myeloma: A Position Statement From The Myeloma Scientific Advisory Group (MSAG) To Myeloma Australia.

Shirlene Sim, Anna Kalff, Gina Tuch, Peter Mollee, Joy Ho, Simon Harrison, Simon Gibbs, H Miles Prince, Andrew Spencer, Douglas Joshua, Cindy Lee, Silvia Ling, Nick Murphy, Ferenc Szabo, Jeff Szer, Nicholas Weber, Christopher Ward, Dipti Talaulikar, Andrew Zannettino, Hang Quach

Journal article  |  2023  |  Intern Med J

Multiple myeloma (MM) is a disease of older people, yet factors relating to comorbidity and frailty may threaten treatment tolerab..

Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.

H Miles Prince, Martin Hutchings, Eva Domingo-Domenech, Dennis A Eichenauer, Ranjana Advani

Journal article  |  2023  |  Ann Hematol

CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL)..

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.

Kelden Richardson, Simon P Keam, Joe Jiang Zhu, Deborah Meyran, Criselle D'Souza, Sean Macdonald, Kerry Campbell, Michael Robbins, Natalie A Bezman, Kirsten Todd, Hang Quach, David S Ritchie, Simon J Harrison, H Miles Prince, Joseph A Trapani, Misty R Jenkins, Paul A Beavis, Phillip K Darcy, Paul J Neeson

Journal article  |  2023  |  Haematologica

Patients with refractory relapsed multiple myeloma respond to combination treatment with elotuzumab and lenalidomide. The mechanis..

Excellent treatment outcomes from low dose radiation therapy for primary cutaneous CD4 small/medium T-Cell lymphoproliferative disorder.

Jennifer Ward, H Miles Prince, Chris McCormack, Stephen Lade, Odette Buelens, Carrie van der Weyden, Friyana Bhabha, Belinda A Campbell

Journal article  |  2023  |  Radiother Oncol

BACKGROUND AND PURPOSE: Primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder (PCSMLPD) is a benign behaving co..

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Hang Quach, Gurdeep Parmar, Enrique M Ocio, H Miles Prince, Albert Oriol, Nobuhiro Tsukada, Kazutaka Sunami, Pierre Bories, Sumit Madan, Dorothee Semiond, Disa Yu, Sandrine Macé, Florence Suzan, Philippe Moreau

Journal article  |  2022  |  Blood

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania TM Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, et al.

Journal article  |  2022  |  Blood

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Joanne LC Tan, Cameron Wellard, Elizabeth M Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon James Harrison, Emma-Jane McDonald, P Joy Ho, H Miles Prince, Bradley M Augustson, Philip Campbell, Zoe K McQuilten, Erica M Wood, Andrew Spencer

Journal article  |  2022  |  BRITISH JOURNAL OF HAEMATOLOGY

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

Mary Ann Anderson, Leanne Berkahn, Chan Cheah, Michael Dickinson, Maher K Gandhi, Pratyush Giri, Eliza A Hawkes, Anna Johnston, Colm Keane, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Dipti Talaulikar, Judith Trotman, Janne Williams, Erica M Wood, Tasman Armytage, Allison Barraclough, Duncan Carradice, Geoffrey Chong, et al.

Journal article  |  2022  |  BMC MEDICAL RESEARCH METHODOLOGY

BACKGROUND: Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to ..

Subcutaneous (SC) Isatuximab Administration by an On-Body Delivery System (OBDS) in Combination with Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

Quach Hang, Parmar Gurdeep, Enrique M Ocio, HM Prince, Oriol Albert, Tsukada Nobuhiro, Sunami Kazatuka, Bories Pierre, Karanes Chatchada, Madan Sumit, Semiond Dorothee, Inchauspe Marlene, Mace Sandrine, Suzan Florence, Moreau Phillippe

Conference Proceedings  |  2022  |  AMERICAN JOURNAL OF HEMATOLOGY